These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 18005385)

  • 21. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
    Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L
    J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
    Scheubeck G; Hoffmann M; Jurinovic V; Fischer L; Unterhalt M; Schmidt C; Böck HP; Dührsen U; Kaesberger J; Kremers S; Lindemann HW; Mantovani L; Hiddemann W; Hoster E; Dreyling M;
    Ann Hematol; 2024 Jul; 103(7):2373-2380. PubMed ID: 38459156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
    Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H
    Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
    Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
    Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
    Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J
    Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Skarlos D
    Ann Oncol; 2004 Mar; 15(3):493-7. PubMed ID: 14998855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
    Gisselbrecht C; Glass B; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Ketterer N; Shpilberg O; Hagberg H; Ma D; Brière J; Moskowitz CH; Schmitz N
    J Clin Oncol; 2010 Sep; 28(27):4184-90. PubMed ID: 20660832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    Witzens-Harig M; Memmer ML; Dreyling M; Hess G
    BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Kalykaki A; Papakotoulas P; Tsousis S; Boukovinas I; Kalbakis K; Vamvakas L; Kotsakis A; Vardakis N; Papadopoulou P; Georgoulias V; Mavroudis D;
    Anticancer Res; 2008; 28(1B):495-500. PubMed ID: 18383891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
    Sirohi B; Cunningham D; Norman A; Last K; Chau I; Horwich A; Oates J; Chong G; Wotherspoon A
    Hematology; 2007 Apr; 12(2):149-53. PubMed ID: 17454196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
    Gopal AK; Press OW; Shustov AR; Petersdorf SH; Gooley TA; Daniels JT; Garrison MA; Gjerset GF; Lonergan M; Murphy AE; Smith JC; Pagel JM
    Leuk Lymphoma; 2010 Aug; 51(8):1523-9. PubMed ID: 20578815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
    Hou Y; Wang HQ; Ba Y
    Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
    Chau I; Webb A; Cunningham D; Hill M; Rao S; Ageli S; Norman A; Gill K; Howard A; Catovsky D
    Br J Haematol; 2001 Dec; 115(4):786-92. PubMed ID: 11843810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.